EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluation of a Partial Ban on Rx‐Rebates in Germany

Maximilian M Gail, Georg Götz, Daniel Herold iD, Jan T Schäfer iD

Health Economics · 2026-08 · 35 (8) · 1247-1274

DOI: 10.1002/hec.70112 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Health Economics, online erschienen am 18.05.2026. Verfasst von Maximilian M Gail und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Economics, Chair for Industrial Organization, Regulation and Antitrust, Justus Liebig University Giessen. Licher Strasse 62, Giessen, G…. Hauptthemen laut MEDLINE: Prescription Drugs, Pharmaceutical Services, Online, Pharmacies. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AVWL.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We investigate patients' price sensitivity for prescription (Rx) drugs with regards to patronizing online or brick‐and‐mortar pharmacies. In doing so, we exploit a policy change in Germany that prohibited online pharmacies from granting rebates to one part of the population, the members of the statutory health insurance scheme. This policy change created a natural experiment, allowing us to analyze its impact on the pharmaceutical market using Difference‐in‐Differences (DiD). Utilizing a novel dataset obtained from merchandize information systems, we find that the ban led to a shift in consumer behavior, increasing offline pharmacy Rx sales by 1.42%–1.67%. In a second step, we assess to what extent the policy change achieved its alleged goal of supporting brick‐and‐mortar pharmacies. Our findings indicate that pharmacies with low revenues, which are most exposed to market exit, saw only a minor increase in annual revenues of around € 1587. At the same time, pharmacies in the highest decile gained roughly four times that amount. This indicates that the policy change alone was insufficient to reverse the declining trend in pharmacy numbers in Germany. To strengthen the comprehensive supply of pharmaceuticals to the general population, additional reforms seem necessary.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prescription DrugsPharmaceutical Services, OnlinePharmaciesGermanyHumansDrug Costs

Substanzen

Prescription Drugs

Autor:innen und Institutionen

  • Department of Economics, Chair for Industrial Organization, Regulation and Antitrust, Justus Liebig University Giessen. Licher Strasse 62, Giessen, Germany.

ORCID-Profile: Daniel Herold, Jan T Schäfer

Förderung

  • AVWL

Zitieren

APA

Gail, M. M., Götz, G., Herold, D., & Schäfer, J. T. (2026). Evaluation of a Partial Ban on Rx‐Rebates in Germany. Health Economics, 35(8), 1247-1274. https://doi.org/10.1002/hec.70112

Vancouver

Gail MM, Götz G, Herold D, Schäfer JT. Evaluation of a Partial Ban on Rx‐Rebates in Germany. Health Economics. 2026;35(8):1247-1274. doi:10.1002/hec.70112

BibTeX
@article{Gail2026,
  author = {Gail, Maximilian M and Götz, Georg and Herold, Daniel and Schäfer, Jan T},
  title = {Evaluation of a Partial Ban on Rx‐Rebates in Germany},
  journal = {Health Economics},
  year = {2026},
  volume = {35},
  number = {8},
  pages = {1247--1274},
  doi = {10.1002/hec.70112}
}
Kostenlos starten →